Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATHS-T2D: Physiologic and Pharmacologic Responses to Orforglipron
NCT07739537Phase 4Not yet recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2026
- Primary completion
- Sep 2029
01
Overview
Phase 4, open-label trial of orforglipron in type 2 diabetes mellitus (T2DM) and prediabetes (2 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Physiologic characterization by MMTT at 1 day and The acute drug challenges at 12 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)prediabetes
Beyond the preview
Go deeper on NCT07739537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07739537.